CSB produces VeRSaMAbs, recombinant monoclonal antibodies that are extensively validated in‑house for high specificity across applications such as flow cytometry and immunofluorescence. By providing detailed protocols and a curated FAQ, they help researchers select the right antibody the first time, saving lab time and reducing experimental uncertainty.
Funding
Funding not disclosed
Founders
Product
Problem
Researchers often encounter unreliable commercial antibodies that lack specificity or are insufficiently validated, leading to wasted time, failed experiments, and ambiguous data in assays such as flow cytometry and immunofluorescence.
Solution
Cell Surface Bio (CSB) offers VeRSaMAbs, a line of recombinant monoclonal antibodies that are produced and fully validated in‑house for high specificity across multiple applications. Each antibody is accompanied by detailed protocols and a curated FAQ to guide users in assay selection and execution, reducing trial‑and‑error. By focusing on recombinant production, CSB ensures batch‑to‑batch consistency and eliminates variability common with traditional hybridoma‑derived reagents. The company also provides a custom‑antibody service, VeRSa‑Select™, to generate validated antibodies for challenging targets, extending the same quality standards to bespoke research needs.
Target Audience
Primary customers are life‑science researchers and laboratories that require reliable antibodies for cell‑surface and intracellular protein detection, including academic, biotech, and pharmaceutical R&D teams.
Features
- Recombinant monoclonal antibodies with extensive in‑house specificity validation for flow cytometry, immunofluorescence, and other assays
- Consistent batch production ensuring reproducible performance across experiments
- Ready‑to‑use detailed protocols for surface and intracellular epitope detection
- Comprehensive FAQ resource addressing common purchasing and technical questions
- Custom antibody development (VeRSa‑Select™) for difficult or novel protein targets
- Mouse‑derived antibodies covering a range of human cell‑surface markers (e.g., GLUT4, CD7, CD338)